Uno Studio di Fase III di BNT324 Versus Docetaxel nel Carcinoma Prostatico Metastatico Resistente alla Castrazione
Uno studio di fase III, randomizzato, in aperto di BNT324 rispetto a Docetaxel con Prednisone/Prednisolone nel carcinoma prostatico metastatico resistente alla castrazione
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC.
The main goals of this study are:
- To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival [rPFS]).
- To find out if BNT324 helps participants live longer overall (overall survival [OS]).
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The study consists of a screening period (up to 28 days), a treatment period with 21-day cycles, and an after-treatment period that includes a 30-day safety follow-up period and a long-term survival follow-up period.
Treatment continues until the cancer clearly gets worse (in scans, based on blinded independent central review [BICR] assessment or investigator's decision), side effects become unacceptable, the participant chooses to stop, or the study ends.
Participants are put into one of two groups in a 1:1 ratio, which means they will have an equal chance to be in either treatment group, i.e., BNT324 group, or docetaxel plus prednisone/prednisolone group (current SoC). An independent committee will help ensure participant safety, by regularly reviewing safety and early results.
For each participant, the treatment and follow-up periods are projected to be up to ~58 months.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: BioNTech clinical trials patient information
- Numero di telefono: +49 6131 9084
- Email: patients@biontech.de
Luoghi di studio
-
-
-
Southport, Australia, 4215
- Reclutamento
- Tasman Onco Research Pty Ltd
-
-
-
-
-
Brussels, Belgio, 1200
- Reclutamento
- Cliniques Universitaires Saint-Luc
-
-
-
-
-
Beijing, Cina, 100142
- Reclutamento
- Beijing Cancer Hospital
-
Beijing, Cina, 100034
- Reclutamento
- Peking University First Hospital
-
Changsha, Cina, 410005
- Reclutamento
- The First Affiliated Hospital of Hunan Normal University
-
Chengdu, Cina, 610041
- Reclutamento
- West China Hospital, Sichuan University
-
Chongqing, Cina, 400072
- Reclutamento
- The Second Affiliated Hospital of Chongqing Medical University
-
Fuzhou, Cina, 350001
- Reclutamento
- Fujian Medical University Union Hospital
-
Hangzhou, Cina, 310022
- Reclutamento
- Zhejiang Cancer Hospital
-
Hangzhou, Cina, 310016
- Reclutamento
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hefei, Cina, 230601
- Reclutamento
- Second Hospital of Anhui Medical University
-
Nanchang, Cina, 330006
- Reclutamento
- The First Affiliated Hospital of Nanchang University
-
Nanjing, Cina, 210008
- Reclutamento
- Nanjing Drum Tower Hospital
-
Shanghai, Cina, 200032
- Reclutamento
- Shanghai Cancer Center
-
Shanghai, Cina, 200072
- Reclutamento
- No. 10 People's Hospital of Shanghai
-
Wenzhou, Cina, 325000
- Reclutamento
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Cina, 430079
- Reclutamento
- Hubei Cancer Hospital
-
Wuhan, Cina, 420104
- Reclutamento
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhu, Cina, 241001
- Reclutamento
- Yijishan Hospital of Wannan Medical College
-
Yantai, Cina, 264000
- Reclutamento
- Yantai Yuhuangding Hospital
-
-
-
-
-
Dresden, Germania, 1307
- Reclutamento
- Universitätsklinikum Carl Gustav Carus
-
Hamburg, Germania, 22763
- Reclutamento
- Asklepios Klinik Altona
-
-
-
-
-
Krakow, Polonia, 30-727
- Reclutamento
- Pratia MCM Krakow
-
Warsaw, Polonia, 02-781
- Reclutamento
- National Research Institute of Oncology - National Research Institute (NIO-PIB)
-
-
-
-
-
Cambridge, Regno Unito, CB2 0QQ
- Reclutamento
- Addenbrooke's Hospital
-
Cardiff, Regno Unito, CF14 2TL
- Reclutamento
- Velindre Cancer Centre
-
Leeds, Regno Unito, LS9 7TF
- Reclutamento
- St James's University Hospital
-
London, Regno Unito, SW3 6JJ
- Reclutamento
- Royal Marsden Hospital
-
Newcastle upon Tyne, Regno Unito, NE7 7DN
- Reclutamento
- Freeman Hospital
-
Southampton, Regno Unito, SO16 6YD
- Reclutamento
- Southampton General Hospital
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Royal Marsden Hospital
-
-
-
-
California
-
Santa Barbara, California, Stati Uniti, 93105
- Reclutamento
- Sansum Clinic
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Rocky Mountain Cancer Centers
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33901
- Reclutamento
- Florida Cancer Specialists- Fort Myers
-
St. Petersburg, Florida, Stati Uniti, 33701
- Reclutamento
- Florida Cancer Specialists- St. Petersburg
-
West Palm Beach, Florida, Stati Uniti, 33401
- Reclutamento
- Florida Cancer Specialists- West Palm Beach
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30318
- Reclutamento
- Piedmont Cancer Institute
-
-
Illinois
-
Niles, Illinois, Stati Uniti, 60714
- Reclutamento
- Illinois Cancer Specialists
-
Peoria, Illinois, Stati Uniti, 61615
- Reclutamento
- Illinois CancerCare PC
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Reclutamento
- Maryland Oncology Hematology
-
-
New York
-
Albany, New York, Stati Uniti, 12206
- Reclutamento
- NYOH Albany Cancer Center
-
White Plains, New York, Stati Uniti, 10601
- Reclutamento
- White Plains Hospital
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45242
- Reclutamento
- Oncology/Hematology Care, Inc.
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- START Carolinas
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Stati Uniti, 78731
- Reclutamento
- Texas Oncology South Austin
-
Houston, Texas, Stati Uniti, 77024
- Reclutamento
- Texas Oncology Gulf Coast
-
Tyler, Texas, Stati Uniti, 75702
- Reclutamento
- Texas Oncology, P.A. - Tyler
-
Wichita Falls, Texas, Stati Uniti, 76310
- Reclutamento
- Texas Oncology - West Texas
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Virginia Cancer Specialists PC
-
Norfolk, Virginia, Stati Uniti, 23502
- Reclutamento
- Virginia Oncology Associates
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed consent).
-
Must have documented progressive prostate cancer based on at least one of the following criteria:
- Serum/plasma PSA progression, by local laboratory, defined as two consecutive increases in PSA over a previous reference value, each measured sequentially at least 1 week apart. The PSA value at screening is required to be ≥1.0 ng/mL.
- Radiographic soft tissue progression as per PCWG3-modified RECIST v1.1.
- Radiographic progression of bone disease: evaluable disease or new bone lesion(s) by bone scan per PCWG3 criteria.
-
Had previously received one or two prior androgen receptor pathway inhibitor treatments and experienced disease progression during or after a minimum of 8 weeks of therapy.
-
Must not have received systemic cytotoxic chemotherapy, including taxane-based chemotherapy, for mCRPC.
-
Must have had prior orchiectomy and/or have ongoing androgen-deprivation therapy and a castrate-level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L). Participant being treated with luteinizing hormone-releasing hormone agonists or antagonists must continue such treatment throughout the study.
-
Must have an Eastern Cooperative Oncology Group performance score of 0 or 1.
Key Exclusion Criteria:
- Have received prior treatment with B7-H3 targeted therapy, including B7-H3 ADCs.
- Have uncontrolled or significant cardiovascular disease, as defined in the protocol.
- Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or have current ILD/pneumonitis.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: BNT324
|
Intravenous infusion
Altri nomi:
|
|
Comparatore attivo: Docetaxel più prednisone/prednisolone
|
Intravenous infusion Oral |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
rPFS assessed by BICR
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
OS
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. OS is defined as time from randomization to death from any cause. |
From randomization to end of study, i.e., up to 58 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to first subsequent therapy (TFTS)
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. TFST is defined as time from randomization to initiation of the first subsequent systemic anticancer therapy or death, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Objective response rate (ORR)
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. ORR is defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per PCWG3-modifed RECIST v1.1 as assessed by BICR) is observed as best overall response. |
From randomization to end of study, i.e., up to 58 months
|
|
Duration of response (DOR)
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. DOR is defined as time from first objective response (confirmed CR or PR per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) to first occurrence of objective tumor progression (progressive disease per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to pain progression (TTPP)
Lasso di tempo: From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
By arm. TTPP is defined as time from randomization to pain progression as determined by Brief Pain Inventory-Short Form Item 3 "worst pain in 24 hours" and opiate analgesic use (Analgesic Quantification Algorithm score). |
From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
|
rPFS as assessed by investigator
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per PCWG3-modified RECIST v1.1 criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to first symptomatic skeletal-related event (SSRE)
Lasso di tempo: From randomization to end of study, i.e., up to 58 months
|
By arm. Time to first SSRE is defined as time from randomization to first occurrence of any of the following SSREs:
|
From randomization to end of study, i.e., up to 58 months
|
|
Time to prostate-specific antigen (PSA) progression (by central lab testing results)
Lasso di tempo: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. Time to PSA progression is defined as time from randomization to PSA progression per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
PSA response (by central lab testing results)
Lasso di tempo: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. PSA response is defined as having a post-baseline PSA reduction ≥50% from baseline with a consecutive confirmation assessment at least 3 weeks later per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs
Lasso di tempo: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
TEAEs by relationship and by arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
|
Number and percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEs
Lasso di tempo: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
By arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: BioNTech Responsible Person, BioNTech SE
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BNT324-03
- 2025-524445-27-00 (Ctis)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .